Research reveals that over 15 million individuals in the US, UK, Germany, and France are unknowingly affected by metabolic dysfunction-associated steatotic liver disease (MASLD), a severe condition linked to liver fat accumulation. MASH, the more aggressive subset of this disease, leads to serious health risks including cirrhosis and cardiovascular disease but goes largely undiagnosed. Current statistics show only 18% of cases are diagnosed, prompting calls for an improved screening strategy targeting high-risk groups like those with type 2 diabetes and obesity. Non-invasive screening techniques are now available and recommended for better diagnosis rates.
The research highlights that over 15 million people in key Western nations unknowingly suffer from metabolic dysfunction-associated steatotic liver disease, emphasizing urgent diagnostic awareness.
Aggressive fatty liver disease, known as metabolic dysfunction-associated steatohepatitis, is alarmingly prevalent yet underdiagnosed, necessitating improved screening methods to help millions.
Collection
[
|
...
]